Revance to present RT002 data at January conference, says highlights efficacy
Revance Therapeutics announced presentations of clinical data for DaxibotulinumtoxinA Injectable, or RT002, at the TOXINS 2017 conference January 18-21. The presentations include final data from the Phase 2 BELMONT trial and interim results from a separate Phase 2 study of RT002 in isolated cervical dystonia. "These presentations highlight the safety, efficacy and duration-of-effect results for RT002 injectable from prior studies in both low and high dose indications. We are excited by the prospects of developing a next-generation neurotoxin with an improved safety profile, enhanced treatment effectiveness and long duration, whether for facial aesthetics, acute conditions or chronic disease states. We look forward to reporting results from four ongoing RT002 clinical trials in 2017, including the two SAKURA Phase 3 pivotal trials in glabellar lines, the final results for the Phase 2 trial in cervical dystonia and topline results from a Phase 2 trial for plantar fasciitis," remarked CEO Dan Browne.